As an aside, the development of both 'drugs' came from fundamental research in immunology. Not from research directed at wiping out cancer.
The research of 2018 Nobel Prize winner Allison, 70, ultimately resulted in ipilimumab (Yervoy)
and the work of the other Nobel prize winner this year (Honjo, 76) resulted in nivolumab (Opdivo).
In the trial mentioned above both drugs are combined.science.sciencemag.org/content/362/6410/13
Post Edited (Sr Sailor) : 10/11/2018 5:56:42 PM (GMT-6)